Advertisement

Topics

Latest "Zenobia Therapeutics" News Stories - Page: 4

05:18 EDT 20th September 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 76–100 of 7,800+

Probably Relevant

TapImmune agrees to merge with Marker Therapeutics

US-based immunotherapies company TapImmune has signed a definitive merger agreement to buy multi-antigen T-cell therapy platform developer Marker Therapeutics. The...Read More... The post TapImmune agrees to merge with Marker Therapeutics appeared first on Pharmaceutical Technology.


Pear Therapeutics closes $50mm Series B round

Pear Therapeutics Inc. (prescription digital therapeutics) closed a $50mm Series B financing round led by Temasek, which join...

Novartis, Pear co-develop digital therapeutics for MS and schizophrenia

Novartis AG and Pear Therapeutics Inc. are together developing candidates from Pear's prescription digital therapeutics pipel...


iTeos Therapeutics: Combating cancer using immunotherapy against novel target combinations

iTeos Therapeutics is a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL). Focused on expanding the benefits of immunotherapy for cancer patients, the company is developing a proprietary pipeline targeting A2A, immune checkpoints and non-inflamed tumors. Adrian Dawkes speaks to Christophe Queva, CEO of iTeos Therapeutics.

Phase III miss wipes 60% off VBL Therapeutics share price

Shares in Nasdaq-listed VBL Therapeutics collapsed today after the Modiin, Israel-based oncology specialist…

United Therapeutics to acquire SteadyMed

United Therapeutics Corp. is paying $4.46 per share in cash (a 55% premium) to acquire SteadyMed Ltd. United Therapeutics wil...

Capricor Therapeutics, Inc.: Capricor Therapeutics to Present at the MicroCap Conference on April 9, 2018

LOS ANGELES, CA / ACCESSWIRE / April 6, 2018 / Capricor Therapeutics (NASDAQ: CAPR) today announces that AJ Bergmann, Chief Financial Officer will be a featured presenter at the MicroCap Conference...

Magenta’s Bastiano Sanna Appointed Semma Therapeutics CEO

Bastiano Sanna has been named CEO and president of Semma Therapeutics. Elizabeth Stoner, who has been serving as interim CEO, will remain as an advisor to the company. Sanna comes to Cambridge, MA-based Senna from Magenta Therapeutics, where he was chief operating officer. His experience also includes positions at Novartis (NYSE: NVS). Semma is developing […]

Evox Therapeutics expands into new facilities at Oxford Science Park

The exosome therapeutics company announced the expansion will enhance its research and development capabilities and will facilitate its growth

Vectalys, Flashcell Merge to Form New Gene Therapy Company

Flash Therapeutics to develop RNA-based therapeutics and provide broad lentiviral development and manufacturing services

Capricor Therapeutics initiates HOPE-2 trial in US

Capricor Therapeutics has initiated the HOPE-2 clinical trial of CAP-1002 to treat patients with advanced stages of Duchenne muscular dystrophy,...Read More... The post Capricor Therapeutics initiates HOPE-2 trial in US appeared first on Drug Development Technology.

JW Therapeutics brings in $90mm through Series A round

JW Therapeutics (Shanghai) Co. Ltd. (cell-based immunotherapies for cancer) raised $90mm through its Series A round. Investor...

Specialists Rethink Lung Cancer Treatment Plans, With Eye On IO Biomarkers

Plenary speaker at this year's meeting, Leena Gandhi, envisioned a future where individual patients receive a precisely defined immunotherapy regimen.   

Leap Therapeutics to Evaluate TRX518 with Merck and Pfizer

According to the collaboration terms, Leap Therapeutics will conduct a Phase 1/2 clinical trial in advanced solid tumors in patients with relapsed/refractory ovarian, breast and prostate cancers. The post Leap Therapeutics to Evaluate TRX518 with Merck and Pfizer appeared first on Investing News Network.

Alexion bids $791m for rare disease biotech Wilson Therapeutics

Alexion Pharmaceuticals wants to buy Swedish rare diseases biotech Wilson Therapeutics for around $791 million, which is developing a late-stage drug to treat the inherited condition Wilson Disease. In a statement Wilson Therapeutics’ board said i...

Alexion bids $855m for rare disease biotech Wilson Therapeutics

Alexion wants to buy Swedish rare diseases biotech Wilson Therapeutics for around $855 million, which is developing a late-stage drug to treat the inherited condition Wilson Disease. In a statement Wilson Therapeutics’ board said it unanimously re...

Summit Therapeutics plc: Notice of 1st Quarter Results

Summit Therapeutics plc ('Summit', or the 'Company')Summit Therapeutics Provides Notice of Financial Results for the First Quarter Ended 30 April 2018Oxford, UK, and Cambridge, MA, US, 1 June 2018...

Report: Patients Worried Digital Therapeutics will Expose Them to Unwanted Surveillance

New research released today by healthcare innovation consultancy Enspektos, LLC reveals that digital therapeutics, defined as innovations such as prescription medications with embedded sensors and mobile applications that may one day replace drugs, are rapidly growing in scope and importance globally. The research also highlights deep patient concerns about whether digital therapeutics will expose...

Rubius Therapeutics Names Pablo Cagnoni CEO

Pablo Cagnoni has joined cell therapy developer Rubius Therapeutics as CEO. Cagnoni’s career includes work as both an oncologist and a pharmaceutical executive. He was most recently president and CEO of South San Francisco, CA, cancer drug developer Tizona Therapeutics. Rubius, based in Cambridge, MA, is engineering red blood cells with therapeutic properties. The company […]

Galectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting

Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today it is proceeding with plans for a Phase 3 clinical trial program with its galectin-3 inhibitor GR-MD-02 in NASH cirrhosis, incorporating advice and guidance obtained in a meeting with the US Food and Drug Administration (FDA). As quoted in the press release: … Continued ...

Knight Therapeutics Inc.: Notice of Knight Therapeutics' 2017 Fourth Quarter and Year End Results Conference Call

MONTREAL, QUEBEC -- (Marketwired) -- 03/09/18 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, will release its 2017 fourth quarter and year e...

Appointments: New CEOs For Lundbeck, Voyager & Neos, CSOs For iTeos & Tilos

Deborah Dunsire’s appointment to lead Lundbeck tops this week’s list of new hires; Astellas, Orchard Therapeutics, Voyager Therapeutics, iTeos Therapeutics...   

Infant Bacterial Therapeutics AB: Infant Bacterial Therapeutics publishes prospectus in connection with the list change to Nasdaq Stockholm

On August 30, 2018, Infant Bacterial Therapeutics AB (publ) ("IBT" or the "Company") announced that Nasdaq Stockholm's Listing Committee had approved the admission of the Company's shares of series...

Apricus Biosciences and Seelos Therapeutics Announce Merger

Once the merger is completed, the merged company will be called Seelos Therapeutics and will begin trading on the NASDAQ Capital market under ticker symbol "SEEL." The post Apricus Biosciences and Seelos Therapeutics Announce Merger appeared first on Investing News Network.

TG Therapeutics: Eine sehr gute Gewinnchance für mutige Anleger!

TG Therapeutics ist ein Wirkstoffentwickler, der sich auf die Behandlung von Erkrankungen der B-Zellen spezialisiert hat. Dieser Teil des Immunsystems ist beispielsweise bei lymphatischer Leukämie ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks